Cargando…
CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
CDK4/6 inhibitors have become the mainstay of treatment for patients with advanced hormone receptor positive and Human Epidermal Receptor -2 [ HER-2 ] negative breast cancer. Three CDK 4/6 inhibitor drugs are currently approved and available, including Palbociclib, Ribociclib and Abemaciclib. All th...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cancer Intelligence
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470169/ https://www.ncbi.nlm.nih.gov/pubmed/36200010 http://dx.doi.org/10.3332/ecancer.2022.ed124 |